- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03286257
Can Exercise Training Reduce the Frequency and Severity of Hot Flushes Associated With Breast Cancer Treatment?
October 10, 2023 updated by: Helen Jones, Liverpool John Moores University
In brief, this study sets out to understand if exercise training can reduce the frequency and severity of hot flushes associated with breast cancer treatment.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In detail, the aim of this research project is to investigate whether improving temperature control mechanisms including vascular function, with exercise training is beneficial in alleviating hot flushes in breast cancer patients and their associated quality of life symptoms.
Participants will be recruited at least 3-months post breast cancer treatment (surgery, radio-therapy, chemotherapy).
This time point has been chosen for this study to allow patients to fully engage in the exercise intervention following treatment.
All participants will be asked to attend the laboratory at Liverpool John Moores University on 4 separate occasions; 2 visits pre- and 2 visits following the exercise intervention for data collection including measures of vascular health, physical activity, sedentary behaviour, and fitness.
The investigators will also gain information on food intake and incidence of hot flushes across a 7-day period pre- and post the intervention.
Study Type
Interventional
Enrollment (Actual)
8
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Merseyside
-
Liverpool, Merseyside, United Kingdom, L33AF
- Research Institute for Sport and Exercise Sciences (RISES)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Able to provide written informed consent
- Pre-menopausal, Peri-menopausal or post-menopausal
- >4 hot flushes per day
- Female
- Treated with tamoxifen or aromatase inhibitor
Exclusion Criteria:
- Uncontrolled or severe hypertension (blood pressure > 160/100 mm Hg)
- Any previous injury preventing exercise
- Type 1 or 2 diabetes
- Anti-depressants
- Currently undergoing chemotherapy or radiotherapy
- Current smoker
- Cannot readily read and understand English
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Exercise Intervention
Participants will complete a partially supervised 4 month exercise program consisting of 3-5 sessions/week at a moderate intensity (40-75% heart rate (HR) reserve) at Liverpool Lifestyles gyms.
Participants will be given free access to the Wellness Key System© when using the Lifestyles exercise equipment which allows researchers to remotely track the exercise intensity of participants accurately.
|
A partially supervised 16-week moderate intensity exercise intervention consisting of 3-5 sessions per week.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Thermoregulation
Time Frame: Change from pre- to post- 16 week exercise intervention
|
Participants will wear a tube-lined suit that allows manipulation of skin temperature by heating the water passed through the tubes.
Core temperature will be increased by 1 degree (monitored using a temperature pill) with sweat rate and skin temperature recordings taken at 5minute intervals across 1 hour of heating.
Thermoregulation will be compared during this hour to that of the post-exercise intervention re-test.
|
Change from pre- to post- 16 week exercise intervention
|
|
Change in Skin Blood Flow
Time Frame: Change from pre- to post- 16 week exercise intervention
|
The change in skin blood flow will be measured using laser Doppler probes at the forearm.
|
Change from pre- to post- 16 week exercise intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Cerebral Blood Flow
Time Frame: Change from pre- to post- 16 week exercise intervention
|
Change in cerebral blood flow will be assessed using transcranial Doppler ultrasound to measure brain blood flow.
|
Change from pre- to post- 16 week exercise intervention
|
|
Change in Vascular Function
Time Frame: Change from pre- to post- 16 week exercise intervention
|
Vascular function will be measured via endothelial-dependent flow mediated dilation of the brachial artery and reported as a percentage change.
|
Change from pre- to post- 16 week exercise intervention
|
|
Change in Vascular Structure
Time Frame: Change from pre- to post- 16 week exercise intervention
|
Vascular structure will be measured at the carotid artery using ultrasound imaging to clearly visualise the artery.
The image will be adjusted so artery wall thickness can be clearly seen with a 30 second recording taken at 3 different angles.
The average of the three angles will be calculated with results reported as change in millimetres.
|
Change from pre- to post- 16 week exercise intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Helen Jones, Professor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2016
Primary Completion (Actual)
July 1, 2018
Study Completion (Actual)
July 1, 2018
Study Registration Dates
First Submitted
September 9, 2017
First Submitted That Met QC Criteria
September 13, 2017
First Posted (Actual)
September 18, 2017
Study Record Updates
Last Update Posted (Actual)
October 12, 2023
Last Update Submitted That Met QC Criteria
October 10, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16/NW/0166
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on Exercise Intervention
-
VA Office of Research and DevelopmentRecruitingMobility Impairment | Asymptomatic Carotid Stenosis (50-69%)United States
-
The Miriam HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
University of AarhusRecruiting
-
Glasgow Caledonian UniversityUnknown
-
Turku University HospitalUniversity of Turku; University of Helsinki; Academy of Finland; European Foundation... and other collaboratorsUnknownType 2 Diabetes Mellitus | Healthy VolunteersFinland
-
Hacettepe UniversityHacettepe University Scientific Research Projects Coordination UnitNot yet recruitingSubstrate Oxidation | Postprandial Metabolism | Exercise Physiology | Cardiovascular Risk MarkersTurkey (Türkiye)
-
Medipol UniversityCompleted
-
University Medical Center GroningenDutch Kidney Foundation; Innovation Fund of the Dutch Medical Insurance CompaniesCompletedMetabolic Syndrome | Kidney Transplant | Post-transplant Weight GainNetherlands
-
Istanbul UniversityCompletedGlenohumeral ArthritisTurkey
-
Sheffield Hallam UniversitySheffield Teaching Hospitals NHS Foundation TrustCompletedQuality of Life | Systemic Sclerosis | Raynaud's PhenomenonUnited Kingdom